Application of streptococcus salivarius subsp. Thermophilus Biohalo 23 tablet in preparation of product for treating PFAPA syndrome

Abstract

The invention discloses an application of a streptococcus salivarius subsp. Thermophilus Biohalo 23 tablet in preparation of a product for treating PFAPA (perfringed perfluorooctanoic acid) syndrome. The preservation number of the streptococcus salivarius subsp. Thermophilus Biohalo 23 is DSM34540. The invention further discloses a preparation method of the streptococcus salivarius subsp. Thermophilus Biohalo 23 tablet. The streptococcus salivarius subsp. Thermophilus Biohalo 23 tablet can relieve attack symptoms of PFAPA syndrome patients, can effectively reduce the number of fever times, has a remarkable curative effect on the PFAPA syndrome, and particularly, can remarkably reduce the number of fever times, fever temperature and fever days of the patients through clinical tests, and has a remarkable curative effect on the PFAPA syndrome. Therefore, the streptococcus salivarius subsp. Thermophilus Biohalo 23 tablet disclosed by the invention can be used for treating the PFAPA syndrome.

Description

Technical Field

[0001] The invention relates to the technical field of probiotics, and in particular to application of a Streptococcus salivarius thermophilic subspecies Biohalo23 tablet in the preparation of a product for treating PFAPA syndrome. Background Art

[0002] PFAPA syndrome is the abbreviation of periodic fever-aphthous stomatitis-pharyngitis-lymphadenitis syndrome, also known as periodic fever with aphthous stomatitis, pharyngitis and lymphadenitis. It is related to genetics and is one of the most common periodic fever syndromes.

[0003] PFAPA syndrome is characterized by periodic fever with fixed intervals of 2 to 8 weeks, and typical clinical features accompanied by pharyngitis, aphthous ulcers and cervical lymphadenitis (not all of these three symptoms may occur), and the patient is asymptomatic between attacks. Fever occurs suddenly, often accompanied by chills, and lasts for 3 to 6 days. In addition to fever, PFAPA syndrome is usually accompanied by at least one of the following manifestations: pharyngitis, exudative or non-exudative; mild aphthous ulcers (oral ulcers); lymphadenitis, swollen cervical lymph nodes, or pain; leukocytosis, erythrocyte sedimentation rate and C-reactive protein are common during attacks; fever recurrence is generally regular, with relatively fixed intervals, and laboratory inflammatory indicators return to normal between attacks.

[0004] At present, PFAPA is mainly treated with drugs, such as glucocorticoids, colchicine or cimetidine; these drugs can relieve the symptoms of some patients, but these drugs have certain side effects. In view of this, the present invention is proposed. Summary of the invention

[0005] The purpose of the present invention is to provide an application of a thermophilic Streptococcus salivarius subsp. Biohalo23 tablet in the preparation of a product for treating PFAPA syndrome. The thermophilic Streptococcus salivarius subsp. Biohalo23 tablet of the present invention can relieve the symptoms of PFAPA syndrome patients and can effectively reduce the frequency of fever, and has a significant therapeutic effect on PFAPA syndrome.

[0006] In order to achieve the above-mentioned purpose of the present invention, the following technical solutions are particularly adopted:

[0007] A first aspect of the present invention provides an application of a Streptococcus salivarius thermophilus subspecies Biohalo23 tablet in the preparation of a product for treating PFAPA syndrome, wherein the Streptococcus salivarius thermophilus subspecies Biohalo23 has a deposit number of DSM34540.

[0008] The second aspect of the present invention provides a probiotic tablet, which comprises the thermophilic Streptococcus salivarius subspecies Biohalo23 and auxiliary materials.

[0009] Preferably, the content of Streptococcus salivarius thermophilus subspecies Biohalo23 in each probiotic tablet is not less than 500 million cfu.

[0010] Preferably, the auxiliary materials include crystalline fructose, maltodextrin, magnesium stearate and flavors.

[0011] Preferably, the auxiliary materials consist of 10-15 parts of crystalline fructose, 82-88 parts of maltodextrin, 0.8-1.2 parts of magnesium stearate and 0.2-0.8 parts of flavor.

[0012] Preferably, the flavor includes strawberry flavor.

[0013] Preferably, the mass of each probiotic tablet is 0.9-1 g.

[0014] Compared with the prior art, the beneficial effects of the present invention include at least:

[0015] The thermophilic Streptococcus salivarius subsp. Biohalo23 tablet of the present invention can relieve the symptoms of PFAPA syndrome patients, and can effectively reduce the frequency of fever, and has a significant therapeutic effect on PFAPA syndrome. Specifically, through clinical trials, it can significantly reduce the frequency of fever, fever temperature and fever days of patients, thereby indicating that the thermophilic Streptococcus salivarius subsp. Biohalo23 tablet of the present invention can be used for the treatment of PFAPA syndrome.

[0016] In addition, the thermophilic subspecies Biohalo23 tablets of Streptococcus salivarius of the present invention are easy to take and can ensure that the probiotics are stable and active for a long time. At the same time, the special tablets have a stable melting speed, melting in the mouth in about 3-5 minutes, ensuring that there is enough time for the thermophilic subspecies Biohalo23 strain of Streptococcus salivarius to colonize in the oropharynx. However, other dosage forms have poor therapeutic effects, such as liquid preparations, which quickly reach the stomach and intestines when taken, causing the death of a large number of bacteria in the gastrointestinal environment, and fewer strains are colonized in the oropharynx, resulting in failure to achieve effective therapeutic effects. DETAILED DESCRIPTION

[0017] The following embodiments of the technical solution of the present invention are described in detail in conjunction with the embodiments. The following embodiments are only used to more clearly illustrate the technical solution of the present invention, and are therefore only used as examples, and cannot be used to limit the protection scope of the present invention.

[0018] It should be noted that, unless otherwise specified, the technical terms or scientific terms used in this application should have the common meanings understood by those skilled in the art to which the invention belongs.

[0019] The embodiment of the present invention provides an application of a Streptococcus salivarius thermophilus subspecies Biohalo23 tablet in preparing a product for treating PFAPA syndrome, wherein the Streptococcus salivarius thermophilus subspecies Biohalo23 has a deposit number of DSM34540.

[0020] The preservation unit of the thermophilic subspecies Biohalo23 of Streptococcus salivarius of the present invention is the German Microorganisms Preservation Center, and the strain can be purchased from the German Microorganisms Preservation Center.

[0021] The thermophilic Streptococcus salivarius subsp. Biohalo23 tablet of the present invention can relieve the symptoms of PFAPA syndrome patients, and can effectively reduce the frequency of fever, and has a significant therapeutic effect on PFAPA syndrome. Specifically, through clinical trials, it can significantly reduce the frequency of fever, fever temperature and fever days of patients, thereby indicating that the thermophilic Streptococcus salivarius subsp. Biohalo23 tablet of the present invention can be used for the treatment of PFAPA syndrome.

[0022] In addition, the thermophilic subspecies Biohalo23 tablets of Streptococcus salivarius of the present invention are easy to take and can ensure that the probiotics are stable and active for a long time. At the same time, the special tablets have a stable melting speed, melting in the mouth in about 3-5 minutes, ensuring that there is enough time for the thermophilic subspecies Biohalo23 strain of Streptococcus salivarius to colonize in the oropharynx. However, other dosage forms have poor therapeutic effects, such as liquid preparations, which quickly reach the stomach and intestines when taken, causing the death of a large number of bacteria in the gastrointestinal environment, and fewer strains are colonized in the oropharynx, resulting in failure to achieve effective therapeutic effects.

[0023] Another embodiment of the present invention provides a probiotic tablet, which includes the thermophilic Streptococcus salivarius subspecies Biohalo23 and auxiliary materials.

[0024] By adding auxiliary materials, the activity of the thermophilic subspecies of Streptococcus salivarius Biohalo23 can be better preserved, and the taste of the product can be improved, thereby improving the taste of the probiotic tablets for children.

[0025] In one embodiment, the content of Streptococcus salivarius thermophilus subspecies Biohalo23 in each probiotic tablet is not less than 500 million cfu.

[0026] By limiting the content of the thermophilic subspecies Biohalo23 of Streptococcus salivarius in probiotic tablets, the efficacy of the probiotic tablets can be better improved.

[0027] In one embodiment, the auxiliary materials include crystalline fructose, maltodextrin, magnesium stearate and flavors.

[0028] In some embodiments, the auxiliary materials are composed of 10-15 parts of crystalline fructose, 82-88 parts of maltodextrin, 0.8-1.2 parts of magnesium stearate and 0.2-0.8 parts of flavor.

[0029] In one embodiment, the flavor includes strawberry flavor; in other embodiments, the flavor may be strawberry flavor, apple flavor or orange flavor.

[0030] In one embodiment, the mass of each probiotic tablet is 0.9-1 g.

[0031] The technical solution of the present invention is further described in detail below through specific embodiments.

[0032] Example 1

[0033] This embodiment is a probiotic tablet, which includes the thermophilic Streptococcus salivarius subspecies Biohalo23 and auxiliary materials;

[0034] The content of Streptococcus salivarius thermophilus subspecies Biohalo23 in each probiotic tablet is 1 billion cfu, and the mass of each probiotic tablet is 0.95g;

[0035] The auxiliary materials consist of 10 parts of crystalline fructose, 88 parts of maltodextrin, 0.8 parts of magnesium stearate and 0.2 parts of flavor, wherein the flavor is strawberry flavor.

[0036] Example 2

[0037] This embodiment is a probiotic tablet, which includes the thermophilic Streptococcus salivarius subspecies Biohalo23 and auxiliary materials;

[0038] The content of Streptococcus salivarius thermophilus subspecies Biohalo23 in each probiotic tablet is 1 billion cfu, and the mass of each probiotic tablet is 0.95g;

[0039] The auxiliary materials consist of 15 parts of crystalline fructose, 82 parts of maltodextrin, 1.2 parts of magnesium stearate and 0.8 parts of flavor, wherein the flavor is strawberry flavor.

[0040] Example 3

[0041] This embodiment is a probiotic tablet, which includes the thermophilic Streptococcus salivarius subspecies Biohalo23 and auxiliary materials;

[0042] The content of Streptococcus salivarius thermophilus subspecies Biohalo23 in each probiotic tablet is 1 billion cfu, and the mass of each probiotic tablet is 0.95g;

[0043] The auxiliary materials consist of 12 parts of crystalline fructose, 85.5 parts of maltodextrin, 1 part of magnesium stearate and 0.5 parts of flavor, wherein the flavor is strawberry flavor.

[0044] Experimental example

[0045] This experimental example is a comprehensive study of PFAPA in Streptococcus salivarius thermophilus subspecies Biohalo23 (German strain bank deposit number DSM34540);

[0046] A total of 95 children with PFAPA syndrome were treated, and their symptoms began to appear at an average age of 2 years old;

[0047] The method of taking the probiotic tablets of Example 3 of the present invention was started at an average age of 4.62 years old; two tablets per day, and the average time of taking the probiotic tablets was 6 months.

[0048] Compared with before taking probiotic tablets, the number of fevers in children during the period of taking probiotic tablets was significantly reduced (83% of children had a reduced number of fevers; median 14 vs 6 times, P < 0.001);

[0049] The number of days with fever was significantly reduced (76% of the children had a shorter number of days with fever; median 4 days vs 2 days, P < 0.001);

[0050] The average fever temperature decreased by 1°C (40°C vs 39°C, P<0.001);

[0051] It can be seen that by taking the probiotic tablets, the incidence of symptoms during the onset of PFAPA syndrome is significantly improved and controlled, indicating that the probiotic tablets of the present invention can treat PFAPA syndrome.

[0052] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein by equivalents. These modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present invention, and they should all be included in the scope of the claims and specification of the present invention.

Claims

1. Application of Streptococcus salivarius thermophilus subspecies Biohalo23 tablets in the preparation of products for the treatment of PFAPA syndrome, characterized in that: The deposit number of the thermophilic Streptococcus salivarius subspecies Biohalo23 is DSM34540.

2. A probiotic tablet, characterized in that: The probiotic tablet comprises the thermophilic Streptococcus salivarius subspecies Biohalo23 according to claim 1 and auxiliary materials.

3. The probiotic tablet according to claim 2, characterized in that The content of the thermophilic Streptococcus salivarius subspecies Biohalo23 in each probiotic tablet is not less than 500 million cfu.

4. The probiotic tablet according to claim 2, characterized in that The auxiliary materials include crystalline fructose, maltodextrin, magnesium stearate and flavors.

5. The probiotic tablet according to claim 2, characterized in that: The auxiliary material consists of 10-15 parts of crystal fructose, 82-88 parts of maltodextrin, 0.8-1.2 parts of magnesium stearate and 0.2-0.8 parts of flavor.

6. The probiotic tablet according to claim 4, characterized in that: The flavor includes strawberry flavor.

7. The probiotic tablet according to claim 2, characterized in that: The mass of each probiotic tablet is 0.9-1g.